The Immune System
Under Control
Our Company
AbolerIS Pharma is a Belgian biopharmaceutical company developing a novel approach to the treatment of chronic autoimmune and inflammatory diseases.
Lead Program
AbolerIS Pharma is developing a first-in-class monoclonal antibody based on a novel scientific approach to restore the balance in the immune system.
Our novel and unique therapeutic approaches induce immune tolerance and preserve useful immune responses in inflammatory, autoimmune, and degenerative diseases.
Latest updates
Nantes, France, November 22, 2022 – AbolerIS Pharma is a pre-clinical stage biotech company specialized in the development of innovative immunomodulators for the treatment of transplant rejection, graft-versus-host-disease and auto-immune…
Gosselies, Belgium, September 18, 2023: AbolerIS Pharma (“AbolerIS”), a Belgian biopharmaceutical company developing an entirely novel approach to the treatment of chronic autoimmune and inflammatory diseases, today announced a €27.3…
The GO Immuno meeting 2023, organised by the LabEx IGO (Laboratory of Excellence Immunotherapy-Graft-Oncology) will bring together all the research teams from Nantes, Angers, Rennes and Brest from this research network in immunology and immunotherapy and…